JNNova

with potential applications in cardio-pulmonary and neuro-inflammatory indications.

LATEST NEWS

their lead therapeutic product JN2019 neutralizes the SARS-CoV-2 variants of concern (VOCs), including Omicronn.

Médicament thérapeutique aux propriétés neutralisantes virales pan-corona: Par la Société de biotechnologie d’Ottawa, JN Nova Pharma

JN Nova Pharma Inc. is a biotechnology company headed up by Dr. John Gillard and Dr. Nathan Yoganathan.

JN Nova and Biodextrisnhave teamed up to produce a new COVID-19 therapeutic solution.